# A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

Source: https://onco.cc/trials/nct07664735/  
OnCo record `nct07664735` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of OPB-201 run by Outpace Bio, Inc., now recruiting.

## Summary

A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. is a phase 1 interventional study registered as NCT07664735 by Outpace Bio, Inc., with 30 participants planned, started 2026-06-30. Conditions recorded: Endometrial Cancer Recurrent, Endometrial Cancer, Advanced Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Recurrent, Platinum Resistant Ovarian Cancer and Endometrial Cancers. Interventions recorded: OPB-201.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07664735
- Phase: 1
- Setting: A Phase 1a/b Study to Evaluate the Safety and Efficacy of OPB 201, an Autologous PReferentially Expressed Antigen of MElanoma (PRAME) T Cell Receptor (TCR) T Cell Therapy in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
- Sponsor: Outpace Bio, Inc.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07664735: https://clinicaltrials.gov/study/NCT07664735

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- drugs: [OPB-201](https://onco.cc/drugs/opb-201/)
- companies: [Outpace Bio](https://onco.cc/companies/outpace-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct07664735.json